SHORT COMMUNICATION

Inefficacy of ivermectin and moxidectin treatments against *Dictyocaulus viviparus* in dairy calves

Paul Campbell | Andrew Forbes | Jennifer McIntyre | Taylor Bartoschek | Kayleigh Devine | Kerry O’Neill | Roz Laing | Kathryn Ellis

School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK

Correspondence
Paul Campbell and Kathryn Ellis, School of Biodiversity, One Health and Veterinary Medicine, University of Glasgow, Glasgow, UK.
Email: P.Campbell.5@research.gla.ac.uk and Kathryn.Ellis@glasgow.ac.uk

Funding information
James Herriot Scholarship (Glasgow University Vet Fund); MSD Animal Health Summer Studentship; Hannah Dairy Research Fund Summer Studentship; Wellcome Clinical Research Career Development Fellowship, Grant/Award Number: 216614/Z/19/Z; University of Glasgow Lord Kelvin Adam Smith Fellowship

Abstract

**Background:** The bovine lungworm *Dictyocaulus viviparus* negatively impacts bovine health and leads to substantial economic losses. Lungworm infections can be difficult to manage due to the unpredictable and severe nature of clinical outbreaks. Despite the widespread use of macrocyclic lactones (MLs) in grazing cattle in the UK, there have been no confirmed reports of resistant lungworms to date, with only one case of anthelmintic-resistant (ML) lungworm confirmed worldwide.

**Methods:** Lungworm Baermann filtrations were conducted on first-season grazing dairy calves as part of a wider study investigating anthelmintic resistance in gastrointestinal nematodes in Scotland using the faecal egg count reduction test.

**Results:** Clinical signs and significant numbers of lungworm larvae in faeces were observed after treatment with either ivermectin or moxidectin.

**Limitations:** There are no established guidelines for the diagnosis of resistant lungworms in the field. Currently, resistance can only be diagnosed after a controlled efficacy test has been conducted. This limits the conclusions that can be drawn; however, they are highly suggestive of resistance.

**Conclusion:** This short report describes the inefficacy of ivermectin and moxidectin against *D. viviparus* and is highly suggestive of ML resistance.

INTRODUCTION

Parasitic bronchitis is caused by the bovine lungworm *Dictyocaulus viviparus*. Lungworm infections can cause mild to severe respiratory distress, inappetence and, in severe cases, death.1,2 *Dictyocaulus viviparus* is regarded as one of the most pathogenic endoparasites of cattle in the UK and is of severe welfare and economic concern. When exposed to a high level of challenge, youngstock with limited immunity are at significant risk of clinical disease.3 In the UK, lungworm outbreaks have been increasing since 2009 and are most pronounced in Scotland and northern England, with a shift in seasonality from late summer/autumn to any time of year and a wider temporal distribution of reported clinical cases, although there is still a peak incidence in September.4

Despite the availability of a vaccine (Bovilis Huskvac, MSD Animal Health), there has been a decrease in its use since the advent of anthelmintic products belonging to the macrocyclic lactone (ML) class.5,6 Reliance on a single anthelmintic class would be expected to select for resistance, as has rapidly occurred in gastrointestinal nematode (GIN) populations.7 However, to our knowledge, only one case of confirmed resistance has been reported worldwide,8,9 although two reports of lack of efficacy of eprinomectin in lactating dairy cows were reported in 2018 and 2020.8,10 This short report describes the inefficacy of ivermectin and moxidectin treatment against *D. viviparus* and is highly suggestive of ML resistance.

MATERIALS AND METHODS

**Farm information**

The study was undertaken on a commercial dairy unit located in central Scotland. The region has
average annual maximum/minimum temperatures of 12.7°C/5.7°C and an average annual rainfall of 1370.2 mm over 181.2 days. The monthly meteorological data for 2023 varied appreciably from those of the previous 30 years. On average, June was 3.2°C warmer, experienced 13.7 mm less rainfall and 87.8 more sunshine hours. On average, July was 0.4°C warmer, experienced 39.6 mm more rainfall and 10.9 fewer sunshine hours (Table S1).

The herd comprised 170 Holstein-Friesian milking cows and followers, totalling 400 individuals; no other stock was grazed on the holding. The herd had been closed for more than 10 years, with service by artificial insemination and an all-year-round calving pattern. Dairy X Beef male calves were reared and sold to slaughter at 24–32 months of age, with dairy heifers retained as replacements. The farm was recruited as part of a study investigating anthelmintic inefficacy in GIN using the faecal egg count reduction test (FECRT).

**Study design**

Thirty-three spring-born Holstein-Friesian heifer and Dairy X Beef first grazing season (FGS) calves were turned out onto 4.4 ha of permanent pasture on 2 May 2023 at a stocking density of 7.5 individuals/ha. The pasture had not been previously grazed that year and was only used for turnout of FGS calves. The calves are usually set-stocked from turnout in late April/early May until mid-September and then moved to new grazing until housing in mid-October. For seven years prior to the 2023 grazing season, all FGS calves were treated with moxidectin (Cydec tin 10% LA Solution; Zoetis) at turnout and ivermectin (Enovex 0.5%, w/v, Pour-on Solution; Norbrook Laboratories) at housing. In previous years, calves were reported to have maintained good body condition and growth rates, there were no confirmed diagnoses of parasitic bronchitis on the farm and lungworms were not a significant concern to the farmer.

The 33 calves were not wormed at turnout, and faecal egg counts (FEC) and body conditions were monitored fortnightly from early July 2023 until the FEC reached a group average of ∼100 eggs per gram (epg). In addition, opportunistic faecal samples were collected for lungworm detection using a modified Baermann filtration technique with a reported sensitivity of one patent female adult. Freshly voided faeces were collected from pasture for this monitoring phase and Baermann filtrations were performed within 4 hours of collection by adding 30 g of faecal material to a 12-ply gauze, forming a pouch and suspending it in a 500 mL glass beaker of tepid water overnight. The following morning, the faecal material was added to a Petri dish, and larvae were identified under a stereo microscope at 10× magnification (see Figure 1). High larva counts were estimated by evenly distributing the sediment onto a scored Petri dish and counting the larvae present in one-quarter of its surface area. Multiple individuals were confirmed as *D. viviparus* by capillary sequencing of the ITS2 region using generic strongyle primers.

On 21 July 2023, the group mean FEC reached 94 epg (range 68–178 epg). Fourteen days later (day 0 in the FECRT), half of the group (16 individuals) were treated with moxidectin (Cydec tin 10% LA Solution for Injection; Zoetis) by subcutaneous ear injection and the other half (17 individuals) were treated with subcutaneous ivermectin (IVOMEC Classic Injection for Cattle and Sheep; Boehringer Ingelheim) at the manufacturers’ recommended dose rates of 1.0 and 0.2 mg/kg bodyweight, respectively. Individual animal weight was estimated by dairy calf weight band (AHDB) according to the manufacturer’s instructions with the calves’ weight ranging from 190 to 230 kg. All dose calculations and administration of the anthelmintics were undertaken by the researchers. Individual per-rectum samples were collected from all animals for FEC on days 0 and 15. From the post-treatment groups, nine samples per group were randomly selected and processed for Baermann filtration.

**RESULTS**

Fifteen Baermann filtrations were performed on a random subset of samples collected 21 and 14 days prior to the FECRT (faeces collected from pasture), and no larvae were detected. On these visits, the calves were in good body condition and displayed no clinical signs of parasitic bronchitis or gastroenteritis. On the day of treatment, the calves were in good body condition and displayed no clinical signs, and the farmer was happy with their performance.

On day 15 post-treatment, several calves displayed clinical signs of parasitic bronchitis: intermittent coughing with increased frequency after they were moved to the holding pen. The farmer noted that some of the calves had begun to develop diarrhoea and that the group was not as ‘bright’. Of the 18 per-rectum samples that were chosen for Baermann filtration, 15 to 20 larvae were detected. The group mean for the post-treatment group (median 8.5) was significantly higher than the pre-treatment group (median 0.5) (Mann-Whitney U-test, *p* = 0.0299).

![Figure 1](image.png)

**FIGURE 1** *Dictyocaulus viviparus* L1 recovered by Baermann filtration of a per-rectum faecal sample collected after moxidectin treatment.
analysis, 12 were positive for lungworm: eight from the ivermectin treatment group and four from the moxidectin treatment group (Table 1). The larval counts of the lungworm-positive individuals varied greatly, ranging from 2 to 340.

Following the identification of lungworm larvae in both ivermectin- and moxidectin-treated groups, the case was reported to the Veterinary Medicine Directorate and relevant pharmaceutical companies as an adverse event with a suspected lack of efficacy. All calves were treated with levamisole (Levacide Low Volume 7.5% Oral-Solution; Norbrook Laboratories) and a supportive treatment of flunixin (Finadyne 50 mg/mL Solution for Injection; MSD Animal Health). They were moved from the high-risk pasture to low-risk grazing; silage aftermath that heifers had grazed. Fourteen days after levamisole treatment, a Baermann filtration was conducted on faecal samples from 10 randomly selected individuals, and no larvae were recovered. The calves had maintained good body condition, although a minority still coughed intermittently.

### DISCUSSION

MLs are active against both larval and adult *D. viviparus*, with an efficacy of more than 99% in susceptible populations.13,14 The claimed period of protection from reinfection by lungworms is 28 and 120 days for IVOMEC and Cydectin 10% LA, respectively. Therefore, the larvae that were recovered on day 15 post-treatment were well within this period of activity. The expected speed of action of MLs against *D. viviparus* in order to eliminate adult worms from the lungs is estimated to be ~24 hours,15 so the presence of larvae indicates the presence of patent adults. With a pre-patent period of 21–28 days, the females producing these larvae must have been present at some early developmental stage during the time of treatment. We therefore conclude that both treatments were ineffective, with the findings highly suggestive of an ML-resistant population of *D. viviparus*.

Although there are established guidelines for the detection of anthelmintic resistance in GIN based on the FECRT,16,17 there are currently no guidelines for diagnosing resistance in *D. viviparus*. In the present study, the lack of a pre-treatment (day 0) larvae count meant that a larvae count reduction could not be conducted; however, the feasibility of calculating a reliable percentage reduction in this species is unclear.

We hypothesised that this selection of an ML-resistant *D. viviparus* population arose from repeated and prolonged exposure to moxidectin over multiple years. As this field was only used for FGS calves, which were always treated with a long-acting moxidectin product at turnout, refugia for lungworms would be severely limited. Furthermore, the long half-life of moxidectin provides an extended ‘tail’ where the drug remains in the host but at a sub-therapeutic concentration18; this period and eventual end of protection from reinfection likely coincided with increasing lungworm challenge in late autumn on this farm. In GIN, moxidectin resistance confers high-level cross-resistance to ivermectin,19 and while the lungworm larval counts reported here are consistent with this finding, we are limited in the conclusions that can be drawn from this small study where ivermectin was also used at housing. The FECRT results for GIN infections in the same calves, collected as part of a wider study, identified both ivermectin and moxidectin resistance (88.9% efficacy [lower confidence interval (LCI) = 86.7%, higher confidence interval (HCI) = 92.2%] and 92.8% efficacy [LCI = 91.5%, HCl = 94%] respectively), again suggesting that continued reliance on MLs is not sustainable.

The previous climatic conditions may go some way to explain why a patent lungworm infection was not detected on this farm prior to the FECRT, but bovine lungworm epidemiology is relatively poorly understood. During the 2 months prior to the FECRT, climate conditions differed from those of the 30-year average; June was significantly warmer and drier, whereas July was wetter. It is hypothesised that these dry conditions would have been detrimental to the survival of any free-living nematodes on pasture and would have limited dispersal from the pat.20 However, the humid conditions of July would have promoted the dispersal of larvae that would have accumulated during this period while also promoting survival.20 Given this sequence of events, the sudden onset of disease in mid-August fits nicely with clinical signs expected to develop 22–26 days after the expected high parasite abundance on pasture.4

The prolonged period of protection offered by MLs, especially long-acting products, coupled with their ease of application, make them a popular choice for controlling lungworms and GIN in calves. However, it is imperative that producers and veterinary practitioners consider the possibility of anthelmintic resistance in lungworms and implement sustainable parasite control strategies.21 In particular, vaccination against lungworm infection in calves can be used successfully alongside other management strategies to reduce anthelmintic usage.

---

**Table 1** *Dictyocaulus viviparus* larvae counts of per-rectum samples collected 15 days after ivermectin or moxidectin treatment

<table>
<thead>
<tr>
<th>Ivermectin</th>
<th>Moxidectin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Animal ID</td>
<td>Larvae counted</td>
</tr>
<tr>
<td>1</td>
<td>40</td>
</tr>
<tr>
<td>2</td>
<td>340</td>
</tr>
<tr>
<td>3</td>
<td>12</td>
</tr>
<tr>
<td>4</td>
<td>250</td>
</tr>
<tr>
<td>5</td>
<td>16</td>
</tr>
<tr>
<td>6</td>
<td>51</td>
</tr>
<tr>
<td>7</td>
<td>0</td>
</tr>
<tr>
<td>8</td>
<td>0</td>
</tr>
<tr>
<td>9</td>
<td>0</td>
</tr>
</tbody>
</table>

*a* Estimated larvae count per 30 g faeces.

---

---

20427670, 0, Downloaded from https://bvajournals.onlinelibrary.wiley.com/doi/10.1002/vetr.4265 by University Of Glasgow, Wally Oval Library for rules of use; OA articles are governed by the applicable Creative Commons License
AUTHOR CONTRIBUTIONS
Conceptualisation, methodology, investigation, resources, writing—original draft, writing—review and editing and project administration: Paul Campbell. Conceptualisation, methodology, investigation, writing—original draft, writing—review and editing and supervision: Andrew Forbes and Jennifer McIntyre. Methodology and investigation: Taylor Bartoschek and Kayleigh Devine. Conceptualisation, methodology, investigation, resources, writing—original draft, writing—review and editing, project administration, supervision and funding acquisition: Roz Laing and Kathryn Ellis.

ACKNOWLEDGEMENTS
We gratefully acknowledge the farm that contributed to this study. This work was funded by the James Herriot Scholarship (Glasgow University Vet Fund) (Paul Campbell), the MSD Animal Health Summer Studentship (Taylor Bartoschek) and the Hannah Dairy Research Fund Summer Studentship (Kayleigh Devine). Roz Laing is supported by the Wellcome Clinical Research Career Development Fellowship (216614/Z/19/Z) and the University of Glasgow Lord Kelvin Adam Smith Fellowship.

CONFLICT OF INTEREST STATEMENT
The authors report that they have no conflicts of interest. The funders had no involvement in the design, collection, analysis and interpretation of the data or in the writing or submission of the manuscript.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available in the Supporting Information of this article.

ETHICS STATEMENT
All research procedures as described were approved by the University of Glasgow MVLS College Ethics Committee (project no. 200210097).

ORCID
Paul Campbell https://orcid.org/0000-0001-5418-6566
Jennifer McIntyre https://orcid.org/0000-0003-2579-6693

REFERENCES
9. Molento MB, Depner RA, Mello MHA. Suppressive treatment of abamectin against 
18. Le Jambre LF, Dobson RJ, Lenane IJ, Barnes EH. Selection for anthelmintic resistance by macrocyclic lactones in 
20. Rose JH. The bionomics of the free-living larvae of 

SUPPORTING INFORMATION
Additional supporting information can be found online in the Supporting Information section at the end of this article.

How to cite this article: Campbell P, Forbes A, McIntyre J, Bartoschek T, Devine K, O’Neill K, et al. Inefficacy of ivermectin and moxidectin treatments against 